Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Field
-
Advanced Grant (2025 – 2030). We have developed in vivo single-cell CRISPR technologies to screen for dozens of molecular factors in liver macrophages in vivo. We will apply these technologies to unravel
-
movement disorders and longitudinal cohort management. Together we offer a highly collaborative, translational environment embedded in VIB and the University of Antwerp. Position Drive a clinical
-
initiative investigating how human-specific features of brain development shape early behavior and neural circuit function in autism spectrum disorders (ASD). This position is a joint effort between the
-
in healthy states, genetically perturbed states, and during liver regeneration. On the other hand, you will develop algorithms to disentangle direct intercellular signals from those that are induced
-
Saelens team. Research Project In this research project you will develop probabilistic deep-learning models that automatically extract biological and statistical knowledge from in vivo perturbational omics
-
supported by a Foundation against Cancer (2025 – 2030). We have developed in vivo single-cell CRISPR technologies to screen for dozens of molecular factors in tumor-associated macrophages (TAMs) in vivo. We
-
About VIB VIB is a globally recognized non-profit research institute at the forefront of life sciences. In close partnership with five leading universities in Flanders, we advance scientific
-
the Simons Foundation Autism Research Initiative (SFARI). This collaborative initiative with the labs of Pierre Vanderhaeghen (VIB-KU Leuven) and Franck Polleux (Columbia University) aims to elucidate how
-
About VIB VIB is a globally recognised non-profit research institute at the forefront of life sciences. In close partnership with five leading universities in Flanders, we advance scientific
-
capacity at a three-fold increase. If the remaining liver is too small, the patient has high risk of developing the Small-For-Size Syndrome (SFSS), a post-operative failure causing death of one in three